<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01381445</url>
  </required_header>
  <id_info>
    <org_study_id>113435</org_study_id>
    <nct_id>NCT01381445</nct_id>
  </id_info>
  <brief_title>A Study Assessing GW870086's Potential to Cause Skin Thinning</brief_title>
  <official_title>A Randomised, Double-blind (for GW870086), Placebo-controlled Study of Topical GW870086 Formulation to Explore the Potential for Skin Thinning in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomised, double-blind, placebo-controlled study of topical GW870086 to&#xD;
      explore the potential for skin thinning in healthy adult volunteers after 42±2 days of&#xD;
      treatment. Twenty (20) healthy volunteers will be randomised to receive placebo and GW870086&#xD;
      2% cream, they will also receive either of the following treatments: GW870086 0.2% cream, or&#xD;
      clobetasol propionate 0.05% cream.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomised, double-blind, placebo-controlled study of topical GW870086 to&#xD;
      explore the potential for skin thinning in healthy adult volunteers after 42±2 days of&#xD;
      treatment. The primary objective of this study is to assess the thickness of the skin using&#xD;
      ultrasound. The secondary objectives are to assess skin thinning using a visual scale for&#xD;
      skin atrophy and telangiectasia, safety and tolerability of GW870086 and to assess the&#xD;
      pharmacokinetics of GW870086 administered as a cream for 42±2 days.&#xD;
&#xD;
      Twenty (20) healthy volunteers will be randomised to receive placebo and GW870086 2% cream.&#xD;
      They will also receive either of the following treatments: GW870086 0.2% cream, or clobetasol&#xD;
      propionate 0.05% cream. Subjects will apply all 3 treatments once daily during the 42±2 day&#xD;
      treatment period. However subjects who are randomised to receive the unblinded clobetasol&#xD;
      propionate will only apply this once daily for a maximum of 21±2 days but will continue to&#xD;
      dose with the other 2 treatments. If significant evidence of skin thinning is observed in any&#xD;
      of the treatment arms (25% reduction in skin thickness measured using ultrasound) then&#xD;
      application of this treatment will be discontinued. Three areas of approximately 5 x 5 cm on&#xD;
      the arm will be identified and each treatment will be applied to the same area throughout the&#xD;
      42±2 day treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 14, 2011</start_date>
  <completion_date type="Actual">July 7, 2011</completion_date>
  <primary_completion_date type="Actual">July 7, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in skin thickness using ultrasound between GW870086 (0.2% and 2%) versus placebo</measure>
    <time_frame>Days; 1, 14, 21, 28, 42, 43</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical evaluation of treated skin areas using assessment of clinical signs and symptoms according to the visual scores of skin atrophy and telangiectasia</measure>
    <time_frame>Days; 7, 14, 21, 28, 35, 42, 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The assessment of safety parameters; adverse events, clinical laboratory tests, ECG, and vital signs</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of GW870086</measure>
    <time_frame>Days 14 &amp;amp; 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of GW870086</measure>
    <time_frame>Days 14 &amp; 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of GW870086</measure>
    <time_frame>Days 14 &amp; 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of GW870086</measure>
    <time_frame>Days 14 &amp; 42</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>GW870086 0.2% &amp;amp; GW870086 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GW870086 0.2%, 2% &amp;amp; placebo each applied to an identified area for 42 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GW870086 2% &amp;amp; Clobetasol Propionate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GW870086 2% &amp;amp; placebo applied to an identified area for 42 days, while Clobetasol Propionate is applied to an area for 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW870086 0.2%</intervention_name>
    <description>White to slightly coloured opaque cream</description>
    <arm_group_label>GW870086 0.2% &amp;amp; GW870086 2%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW870086 2%</intervention_name>
    <description>White to slightly coloured opaque cream</description>
    <arm_group_label>GW870086 0.2% &amp;amp; GW870086 2%</arm_group_label>
    <arm_group_label>GW870086 2% &amp;amp; Clobetasol Propionate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobetasol Propionate</intervention_name>
    <description>White cream</description>
    <arm_group_label>GW870086 2% &amp;amp; Clobetasol Propionate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>White to slightly coloured opaque cream</description>
    <arm_group_label>GW870086 0.2% &amp;amp; GW870086 2%</arm_group_label>
    <arm_group_label>GW870086 2% &amp;amp; Clobetasol Propionate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AST (Aspartate aminotransferase), ALT (Alanine aminotransferase), alkaline phosphatase&#xD;
             and bilirubin ≤ 1.5xULN (Upper limit of normal)(isolated bilirubin &gt;1.5xULN is&#xD;
             acceptable if bilirubin is fractionated and direct bilirubin &lt;35%).&#xD;
&#xD;
          -  Healthy as determined by an experienced physician.&#xD;
&#xD;
          -  Male or female between 18 and 55 years of age inclusive.&#xD;
&#xD;
          -  A female subject is eligible to participate if she is of:&#xD;
&#xD;
             • Non-childbearing potential defined as pre-menopausal females with a documented tubal&#xD;
             ligation or hysterectomy; or postmenopausal. Females on hormone replacement therapy&#xD;
             (HRT) and whose menopausal status is in doubt will be required to use one of the&#xD;
             protocol contraception methods if they wish to continue their HRT during the study.&#xD;
&#xD;
          -  Male subjects with female partners of child-bearing potential must agree to use one of&#xD;
             the protocol contraception methods.&#xD;
&#xD;
          -  BMI within the range 19.0 - 29.0 kg/m2 (inclusive).&#xD;
&#xD;
          -  Capable of giving written informed consent.&#xD;
&#xD;
          -  Single QTc, QTcB &lt; 450 msec; or QTc &lt; 480 msec in subjects with Bundle Branch Block.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any sign of weak or fragile skin, striae, or similar, in the areas which will be&#xD;
             evaluated.&#xD;
&#xD;
          -  Tattoos or body art on the upper arms.&#xD;
&#xD;
          -  Foreseeable intensive UV exposure during the study (solar or artificial). Subjects&#xD;
             must not be exposed to direct sunlight or skin tanning devices (e.g. sunbed) for the&#xD;
             duration of the study.&#xD;
&#xD;
          -  A positive pre-study test for Hepatitis B or Hepatitis C antibody within 3 months of&#xD;
             screening.&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary&#xD;
             abnormalities.&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  A positive test for HIV (Human Immunodeficiency Virus) antibody.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study.&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5&#xD;
             half-lives (whichever is longer) prior to the first dose of study medication, unless&#xD;
             in the opinion of the Investigator and GSK Medical Monitor the medication will not&#xD;
             interfere with the study procedures or compromise subject safety.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications or components thereof.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 mL within a 56 day period.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated.&#xD;
&#xD;
          -  Subjects who are kept due to regulatory or juridical order in an institution.&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Consumption of red wine, Seville oranges, grapefruit or grapefruit juice and/or&#xD;
             pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior&#xD;
             to the first dose of study medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>June 16, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113435</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113435</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113435</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113435</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113435</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113435</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113435</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

